Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for Subjective Cognitive Impairment
NCT01261741Phase 2Completed
- Sponsor
- Merz
- Start
- Nov 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of memantine in subjective cognitive impairment (SCI), sponsored by Merz. Started Nov 2010; status: completed.
02
Drugs
memantine
03
Conditions
subjective cognitive impairment (SCI)
Beyond the preview
Go deeper on NCT01261741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01261741.